The EU General Court confirms the EU Commission's decision concerning its first pharma pay-for-delay case (Lundbeck)

Commission, European

Previous article The UK Competition Authority alleges that two pharmaceutical companies have concluded a pay-for-delay agreement (Actavis / Concordia) Next article The EU General Court rules on the legitimacy of settlement agreements in the pharmaceutical sector (Lundbeck)

8 Sep 2016

The EU General Court confirms the EU Commission’s decision concerning its first pharma pay-for-delay case (Lundbeck)

KEYWORDS

Reference

EU General Court, Lundbeck, Case T-472/13, 8 September 2016

Antitrust: Commission welcomes General Court judgments upholding its Lundbeck decision in first pharma pay-for-delay case Today the General Court upheld the Commission's Lundbeck decision and ruled for the first time that pharma pay-for-delay agreements breach EU antitrust rules. In such agreements an original pharmaceutical manufacturer pays generics producers to stay out of the market. The European Commission welcomes today's judgments by the General Court fully upholding its Lundbeck decision (cases T-472/13, T-460/13, T-467/13, T-469/13, T-470/13, T-471/13). The

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

European Commission
European Commission - DG COMP (Brussels)

Belgium 1264 contributions 2613369 visits

Quotation

European Commission, The EU General Court confirms the EU Commission’s decision concerning its first pharma pay-for-delay case (Lundbeck), 8 September 2016, e-Competitions Pay-for-delay agreements, Art. N° 81274

Visites 344